The new risk score was based on two clinical data points, including tumor size and nodal stage, and four different gene signatures, namely immune infiltration, tumor cell proliferation, luminal differentiation, and HER2 amplicon expression [41]. The gene discussed is ERBB2; the disease is neoplasm.